COVID-19. Clinical or epidemiological diagnosis of COVID-19 where laboratory confirmation is inconclusive or not available.
Conditions
Interventions
Intervention group: receiving Sofosbuvir 800mg and Daclatasvir 120mg (two drugs combination of Sofosbuvir 400mg and Daclatasvir 60mg, two tablets per day, Sovodak) produced by :Fanavaran Rojan Mohag
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Both sexes Age higher than 18 years old Diagnosis of COVID 19 Patients that do not need to be admitted in hospital
Exclusion criteria
Exclusion criteria: Patients without consent form Patients that can not come for follow-up Pregnancy , breast feeding Renal insufficiency with eGFR less than 30 , or serum creatinin higher than 2.5 mg/dl in male and 2 mg/dl in female Heart rate less than 50/ min Hepatitis B infection Amiodarone and /or Warfarin consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Related or non -related adverse events. Timepoint: Before intervention and 48 hours after the end of the study (day 12 of study). Method of measurement: Daily follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to clinical recovery. Timepoint: Before intervention and 48 hours after the end of the study (day 12 of study). Method of measurement: Clinical Follow-up.;Hospitalization. Timepoint: Before intervention and 48 hours after the end of the study (day 12 of study). Method of measurement: Clinical follow-up.;Death. Timepoint: Before intervention and 48 hours after the end of the study (day 12 of study). Method of measurement: Clinical follow-up. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAnahita Sadeghi
Tehran University of Medical Sciences
Outcome results
None listed